title: Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
abstract: OBJECTIVE
  To compare the protective effects of resveratrol, gliclazide, and losartan, at biochemical and histopathological levels, on the rat kidney with experimentally induced type 1 diabetes.
  
  
  METHODS
  A total of 35 adult male Wistar rats were divided into control, diabetic, diabetic gliclazide, diabetic resveratrol, and diabetic losartan groups. For biochemical analysis, based on one of the kidneys, superoxide dismutase, malondialdehyde, and catalase were used for measurement. The other kidney was stained for histochemical and immunohistochemical markers and examined by light microscopy.
  
  
  RESULTS
  Nephropathy due to diabetes was developed at the end of the third week in the diabetic group: in the glomeruli, contraction from Bowman distance, diffuse mesangial matrix increasing and tubular dilation, and cytoplasmic vacuolar changes were observed. In tubulointerstitial areas, some tubular structures, an increased expression of VEGF was observed.
  
  
  CONCLUSIONS
  As a result, in diabetic rats, the effects of gliclazide, resveratrol, and losartan cure were equivalent to each other according to the parameters which were followed. Resveratrol, gliclazide, and losartan significantly protected renal glomeruli and the proximal and distal tubules.
authors.forename: Tasdemir
authors.initials: T
authors.lastname: Ezel
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Kocyigit
authors.forename: Engin
authors.initials: E
authors.lastname: Deveci
authors.forename: Yildiz
authors.initials: Y
authors.lastname: Atamer
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Sermet
authors.forename: Ersin
authors.initials: E
authors.lastname: Uysal
authors.forename: Ayfer
authors.initials: A
authors.lastname: Aktaş
authors.forename: Dilek
authors.initials: D
authors.lastname: Yavuz
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005907:Gliclazide / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007150:Immunohistochemistry; D007668:Kidney / Q000187:drug effects*; D019808:Losartan / Q000494:pharmacology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000975:Antioxidants; D007004:Hypoglycemic Agents; D013267:Stilbenes; D005907:Gliclazide; D019808:Losartan; D000077185:Resveratrol